BOSTON, Jan. 22, 2013 /PRNewswire/ -- Replikins Ltd. and Brain Research Associates announced today that specific conserved genomic Replikin peptide sequences for the first time have been found to be shared among different histological cancer types, permitting the seven day synthesis of new shared cancer vaccines.
Each of the shared Replikins was found to be present in multiple malignancies. The genomic Replikin®Count (number of Replikin genomic structures per 100 amino acids) relates quantitatively to the five year human mortality rate for each cancer type, the first genomic structures found to be so related (1) (see Figure). The lowest genomic Replikin®Counts were found in those cancers which have the lowest five year mortality rates, as in prostate and thyroid cancer; and the highest Replikin®Counts were found in glioblastoma multiforme, pancreatic and lung cancer, which have the highest mortality rates.
Genomic Replikins in cancer are quantitatively predictive of mortality rate, as recently also found by Replikins Ltd. in viral infectious disease (1-10), and these Replikin structures enable the production of effective specific synthetic vaccines in seven days (9,10). These genomic Replikins in cancer are also the basis of aids for cancer diagnosis, as the Antimalignin Antibody in Serum (AMAS)®Test, the anti-Replikin antibody test, which was shown to be elevated in all common cancers (1). This test has proved useful in helping to distinguish benign from malignant growths, when the cancer is small and barely detected by radiographic techniques, eg. as an aid in diagnosing cancer early in lung and in breast lesions (1). The AMAS®Test can now also be used as a marker to track cancer prevention by synthetic Replikins vaccines
Copyright©2012 PR Newswire.
All rights reserved